A carregar...
HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researc...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7072136/ https://ncbi.nlm.nih.gov/pubmed/32013157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12020318 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|